Major Moves and Milestones: A Round-up of Health Headlines

The FDA approved Astellas' gastric cancer therapy, CVS Health replaced CEO Karen Lynch amid investor pressure, and Tennessee's medical emergency abortion ban was blocked. Congo's mpox vaccine rollout is slow, B. Braun plans to boost IV fluid production, and WHO suggests front-label health information for packaged foods.

The U.S. Food and Drug Administration (FDA) has approved a new therapy by Astellas to treat gastric cancer, promising a significant impact for patients with cancers in the gastroesophageal junction. The therapy, known as Vyloy, will be used alongside chemotherapy.

Amid investor pressure, CVS Health has undergone a leadership transition, replacing CEO Karen Lynch with David Joyner. This move comes as the firm faces demands to enhance its business trajectory and improve sluggish share prices.

In other health news, Tennessee's court has blocked the enforcement of the state's abortion ban in specific medical emergencies. Meanwhile, the rollout of mpox vaccines in Congo is reportedly slower than anticipated.